Entinostat Prevents Leukemia Maintenance in a Collaborating Oncogene-Dependent Model of Cytogenetically Normal Acute Myeloid Leukemia

Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia

(2012) T. Bhatla et al.   BLOOD

Integration of Next-Generation Sequencing Into Clinical Practice: Are We There Yet?

(2012) Alexander Kohlmann et al.   SEMINARS IN ONCOLOGY

Distinct regulation of c-myb gene expression by HoxA9, Meis1 and Pbx proteins in normal hematopoietic progenitors and transformed myeloid cells

(2012) E Dassé et al.   Blood Cancer Journal

The Pathogenesis of Mixed-Lineage Leukemia

(2011) Andrew G. Muntean et al.   Annual Review of Pathology-Mechanisms of Disease

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML

(2011) J. M. Scandura et al.   BLOOD

Identification and characterization of Hoxa9 binding sites in hematopoietic cells

(2011) Y. Huang et al.   BLOOD

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

(2011) Scott R. Daigle et al.   CANCER CELL

Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia

(2011) D J P M Stumpel et al.   LEUKEMIA

Identification of Candidate Small-Molecule Therapeutics to Cancer by Gene-Signature Perturbation in Connectivity Mapping

(2011) Darragh G. McArt et al.   PLoS One

RNA-seq analysis of 2 closely related leukemia clones that differ in their self-renewal capacity

(2010) B. T. Wilhelm et al.   BLOOD

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

(2010) S. Schwind et al.   BLOOD

Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group

(2010) Torsten Haferlach et al.   JOURNAL OF CLINICAL ONCOLOGY

MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo

(2010) R. K. Srivastava et al.   MOLECULAR CANCER THERAPEUTICS

Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [11C]MS-275 using Positron Emission Tomography

(2009) Jacob M. Hooker et al.   ACS Chemical Neuroscience

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features

(2009) C. Haferlach et al.   BLOOD

sscMap: An extensible Java application for connecting small-molecule drugs using gene-expression signatures

(2009) Shu-Dong Zhang et al.   BMC BIOINFORMATICS

Hierarchical Maintenance of MLL Myeloid Leukemia Stem Cells Employs a Transcriptional Program Shared with Embryonic Rather Than Adult Stem Cells

(2009) Tim C.P. Somervaille et al.   Cell Stem Cell

Mouse models of human AML accurately predict chemotherapy response

(2009) J. Zuber et al.   GENES & DEVELOPMENT

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

(2009) E. M. Ocio et al.   HAEMATOLOGICA

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Favorable Prognostic Impact ofNPM1Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

(2009) Heiko Becker et al.   JOURNAL OF CLINICAL ONCOLOGY

HOXA9 is required for survival in human MLL-rearranged acute leukemias

(2008) J. Faber et al.   BLOOD

A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects

(2008) B. J. Wouters et al.   BLOOD